About XPhyto Laboratories
Innovative applications of psychedelics
Aiming to transform anecdotal knowledge into proven, commercialized solutions for common mental health conditions
An XPhyto Subsidiary
XPhyto Laboratories
Cannabis Cultivation, Extraction, Research and Development
XPhyto’s acquisition of BUNKER Pflanzenextrakte GmbH, a Bavarian-based German cannabis company, brought with it a unique German cannabis cultivation and extraction licence that enables XPhyto Laboratories to cultivate and extract up to 70 different strains of cannabis sativa and cannabis indica for scientific purposes.
In addition, XPhyto Laboratories has an exclusive cannabis research and development agreement with the chair of brewing and beverage technology at the Technical University of Munich (TUM), School of Life Sciences Weihenstephan to develop new CBD-infused beverages to meet growing commercial demand and therapeutic applications.
Exclusive Agreement for Producing Psychedelic Compounds
XPhyto Laboratories’ exclusive agreement with Applied Pharmaceutical Innovation paved the way for industrial-scale production of standardized active pharmaceutical ingredients (APIs), an important part of XPhyto’s psychedelic pharmaceutical program. This agreement enables the synthesis of pharmaceutical grade psychedelic compounds such as mescaline and psilocybin and the parallel development of the standard operating procedures necessary to obtain regulatory approval for the respective commercial production process.
This was a critical step to addressing an anticipated shortage of large-scale supply of certain approved and standardized pharmaceutical grade psychedelics necessary for ongoing research and application.
“Having the ability to develop standardized and efficient API delivery for clinical and therapeutic use is critical to advancing the promising field of psychedelic medicine.”
– Hugh Rogers, CEO
Our Products in Development with XP Laboratories
CBD Oral/Sublingual Strip
Clinical studies are planned in 2021 to advance our research into the potential impact for treatment-resistant Epilepsy.
THC Oral/Sublingual Strip
Clinical studies are planned in 2021 to advance our research into the potential impact for anorexia and nausea.
CBD:THC Oral/Sublingual Strip
Clinical studies are planned in 2021 to advance our research into the potential impact on Multiple Sclerosis-associated spasticity.
Be in the know. Get our press releases and latest news first.
Hear about our latest research, products, exclusive partnerships & more.